(Feb 24): Pfizer Inc has acquired exclusive rights to commercialise an obesity therapy in China, strengthening its push into the fast-growing weight loss market. It “accelerates Pfizer’s long-term strategic planning in the metabolic space and meets the growing needs of Chinese patients,” Jean-Christophe Pointeau, Pfizer’s China president, said in the statement. He noted that obesity affects 14.1% of Chinese adults and has been prioritised under the government’s Healthy China campaign. In a late-stage study, ecnoglutide spurred weight loss on par with Eli Lilly’s Zepbound. Under the deal with Pfizer, Sciwind will still be responsible for the development, registration, manufacturing and supply of the drug.

Source: The Edge Markets February 24, 2026 05:40 UTC